Department of Gynecology, The Affiliated Qingdao Hiser Hospital of Qingdao University, Qingdao Hospital of TraditionalChinese Medicine, Qingdao 266000, China.
Department of Obstetrics and Gynecology, Liaocheng Third People's Hospital, Liaocheng 252000, China.
Cell Mol Biol (Noisy-le-grand). 2020 Jun 5;66(3):85-91.
This study aimed to investigate the expression and prognosis of CyclinA and CDK2 in patients with advanced cervical cancer after chemotherapy. The patient history of 108 patients with advanced cervical cancer admitted to our hospital from December 2013 to January 2016 was selected as a cervical cancer group. 54 normal healthy people admitted to our hospital for physical examination in the same period were selected as the control group. Western blotting and RT-PCR were used to detect the difference between CyclinA and CDK2 proteins and mRNA expression between the two groups and the correlation between them was analyzed. The expressions of CyclinA and CDK2 in serum and the changes in detection index level of squamous cell carcinoma antigen (SCCA), carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF) were observed in cervical cancer group at different stages of treatment. The correlation between the two indexes and SCCA, CEA, VEGF and the 3-year survival and prognostic significance of cervical cancer patients with different CyclinA and CDK2 expressions were analyzed. The relative expressions of CyclinA and CDK2 proteins and mRNA in the cervical cancer group were significantly higher than those in the control group (P< 0.05). Pearson correlation analysis showed a positive correlation between CyclinA and CDK2 proteins and mRNA expressions. After treatment, the expressions of CyclinA, CDK2 mRNA and SCCA, CEA and VEGF were significantly lower than those before treatment (P< 0.05). The 3-year survival rate of CyclinA and CDK2 in the high expression group was significantly lower than that of the low expression group. CyclinA and CDK2 are highly expressed in advanced cervical cancer. The expression is decreased after chemotherapy. The prognosis of both low expressions is higher and the expression is good. It can be used to predict the efficacy and prognosis of cervical cancer in the clinic.
本研究旨在探讨 CyclinA 和 CDK2 在接受化疗的晚期宫颈癌患者中的表达与预后。选取我院 2013 年 12 月至 2016 年 1 月收治的 108 例晚期宫颈癌患者的病史作为宫颈癌组。同期选取我院 54 例健康体检者作为对照组。采用 Western blot 法和 RT-PCR 法检测两组 CyclinA 和 CDK2 蛋白及 mRNA 表达差异，并分析两者的相关性。观察宫颈癌组不同治疗阶段血清中 CyclinA 和 CDK2 的表达变化，检测鳞状细胞癌抗原（SCCA）、癌胚抗原（CEA）和血管内皮生长因子（VEGF）检测指标水平的变化。分析两者与 SCCA、CEA、VEGF 的相关性，以及不同 CyclinA 和 CDK2 表达水平的宫颈癌患者的 3 年生存率及预后意义。宫颈癌组 CyclinA 和 CDK2 蛋白及 mRNA 相对表达均显著高于对照组（P<0.05）。Pearson 相关性分析显示 CyclinA 和 CDK2 蛋白及 mRNA 表达呈正相关。治疗后，CyclinA、CDK2mRNA 及 SCCA、CEA 和 VEGF 表达均显著低于治疗前（P<0.05）。CyclinA 和 CDK2 高表达组 3 年生存率显著低于低表达组。CyclinA 和 CDK2 在晚期宫颈癌中呈高表达，化疗后表达降低，低表达者预后较好，表达良好。可用于预测宫颈癌的疗效和预后。
